Sanofi-Lilly Settlement Paves Way For Biosimilar Lantus

 
• By Jessica Merrill

A potential launch of Eli Lilly & Co.'s copycat version of Sanofi's blockbuster Lantus (insulin glargine) in 2016 will put pressure on the entire insulin category, including new drugs like Novo Nordisk AS's Tresiba (insulin degludec) and Sanofi's own follow-on Toujeo.

More from Alimentary/Metabolic

More from Therapy Areas